BHVN Stock Overview
Focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biohaven Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.29 |
| 52 Week High | US$62.21 |
| 52 Week Low | US$16.45 |
| Beta | 0 |
| 11 Month Change | 13.28% |
| 3 Month Change | 13.09% |
| 1 Year Change | 108.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 465.62% |
Recent News & Updates
Recent updates
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Shareholder Returns
| BHVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.3% | 4.7% | 3.1% |
| 1Y | 108.9% | 15.1% | 24.9% |
Return vs Industry: BHVN exceeded the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: BHVN exceeded the US Market which returned 25.4% over the past year.
Price Volatility
| BHVN volatility | |
|---|---|
| BHVN Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BHVN has not had significant price volatility in the past 3 months.
Volatility Over Time: BHVN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 239 | Vlad Coric | www.biohaven.com |
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
Biohaven Ltd. Fundamentals Summary
| BHVN fundamental statistics | |
|---|---|
| Market cap | US$3.88b |
| Earnings (TTM) | -US$746.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs BHVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$746.61m |
| Earnings | -US$746.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BHVN perform over the long term?
See historical performance and comparison